Location: Home
  • search
  • go
  • Relate News
  • 3/10/2026India Still Relies Heavily on China for Essential Pharmaceutical Ingre...
  • 3/10/2026Novo Nordisk and United Labs Report ~20% Weight Loss With Next‑Gen Tr...
  • 3/10/2026Haleon Expands Oral-Health Presence in China as Western Brands Struggl...
  • 3/10/2026US Weighs Policy Measures to Address China Biotech Competition
  • 3/10/2026China Biotech Dealmaking Defies Seasonal Slowdown as February Licensin...
  • 3/10/2026China Challenges High-Priced Gene Therapies with Lower-Cost Alternativ...
  • 3/9/2026China Biotech Financing Rebounds in Early 2026 as RNA Deals and Global...
  • 3/9/2026Abbisko's Pimicotinib Phase 3 MANEUVER Results Published in The Lancet
  • 3/9/2026Merck KGaA Drops Hengrui-Licensed PARP1 Candidate After Early Clinical...
  • 3/9/2026Hansoh Reports Positive Phase 3 Results for Weekly GLP-1/GIP Dual Agon...
  • 3/9/2026Hansoh's B7-H3 ADC Shows Promising Lung Cancer Activity in Cancer Cell...
  • 3/9/2026iCamuno Biothera Raises Over CNY 100M in Series A3 to Advance iPSC Cel...
  • 3/9/2026Rapport Licenses Seizure Drug Candidate to Tenacia in Greater China
  • 3/9/2026Kelun Biotech and Harbour BioMed's SKB575 Receives IND Clearance in Ch...
  • 3/9/2026Regeneron Highlights Positive Chinese Phase III Data for Obesity Candi...
  • 3/9/2026Biocytogen Achieves Key Clinical Milestone as IDEAYA Initiates Phase I...
  • 3/9/2026NMPA Seeks Input on Draft Guidelines for Quality Summaries of Therapeu...
  • 3/9/2026China Publishes 102nd Batch of Reference Formulations for Generics and...
  • 3/6/2026Sciwind's Ecnoglutide Approved in China for Obesity
  • 3/6/2026Lynk's Zemprocitinib Meets Phase III Endpoints in Atopic Dermatitis
  • 3/6/2026Abbisko Doses First Patient in Trial of KRAS G12D Inhibitor ABSK141
  • 3/6/2026China Approves Novo's Weekly Insulin–GLP-1 Combination Therapy for Ty...
  • 3/6/2026Recent Executive Moves
  • 3/5/2026CDE Issues Guidance on Subject Selection for Oncology Drug Bioequivale...
  • 3/5/2026CMS Wins China Trial Approval for INHBE-Targeting Obesity siRNA Drug
  • 3/4/2026Eli Lilly Advances New Oral Diabetes Therapy in China
  • 3/4/2026Sanofi Licenses Sino Biopharm's Transplant Therapy in $135M Upfront De...
  • 3/4/2026Antengene Strikes $1.1B+ CD19 T-Cell Engager Deal with UCB
  • 3/4/2026Minwei Biotech's siRNA Therapy MWX401 Cleared for Clinical Trials in C...
  • 3/4/2026Immunofoco Raises ~CNY 200M in Pre-IPO Round Ahead of Hong Kong Listin...
  • Page:10/830 Total number of articles:24881: [First][<<] [8] [9] [10] [11] [12] [>>] [End]
  • Site map | Contact Us | Links
  • © Wicon International Group